Early-stage investors haven't lost their interest in biotechnology and health care, as evidenced by the $100 million life sciences fund just closed by Schroder Ventures.

Raising the money wasn't a cakewalk, however. "I don't think we're claiming it was easy," said Jeffrey Collinson, managing partner. "It took much longer than expected - we started over a year ago. We